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Abstract
With the advancement of nanocarriers for drug delivery into biomedical practice, assessments of 
drug susceptibility to oxidative degradation by enzymatic mechanisms of inflammatory cells 
become important. Here, we investigate oxidative degradation of a carbon nanotube-based drug 
carrier loaded with Doxorubicin. We employed myeloperoxidase-catalysed and peroxynitrite-
mediated oxidative conditions to mimic the respiratory burst of neutrophils and macrophages, 
respectively. In addition, we revealed that the cytostatic and cytotoxic effects of free Doxorubicin, 
but not nanotube-carried drug, on melanoma and lung carcinoma cell lines were abolished in the 
presence of tumor-activated myeloid regulatory cells that create unique myeloperoxidase- and 
peroxynitrite-induced oxidative conditions. Both ex vivo and in vitro studies demonstrate that the 
nanocarrier protects the drug against oxidative biodegradation.
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Recent advances in the development of nanomaterials have provided a great opportunity for 
precise engineering in drug delivery.1 Carbon nanotubes are particularly useful for 
intracellular drug delivery2,3 and prolonged circulation times due to the enhanced 
permeability and retention (EPR) effect.4 However, the inherent hydrophobicity of 
nanotubes necessitates surface modifications and functionalization with hydrophilic 
auxiliary components, and thus prediction of the long-term safety is even more complicated. 
Recent demonstration of peroxidase-mediated degradation of oxidized carbon nanotubes5–7 
has increased their potential significance in biomedical applications. The use of degradable 
drug carriers is imperative in clinical applications,8 but their degradation may reduce drug 
efficacy and cause side effects—regardless of whether the degradation is programmed or 
naturally occurs.9 It has been well documented that oxidative enzymes of inflammatory cells
—upon their release into circulation—markedly accelerate oxidative biodegradation of 
numerous classes of drugs, thus affecting their therapeutic potential.10–12 These studies, to 
the best of our knowledge, have not been conducted with nano-delivery drug formulations. 
Because oxidation mechanisms and degradation kinetics are highly dependent on the 
functional groups and surface properties of nanotubes as well as interactions with various 
endogenous oxidants,13 the degradation characteristics of drug carriers should be thoroughly 
studied in the process of developing a new paradigm for carbon nanotube-based drug 
delivery.
This paper investigates the lifespan of the drug and the degradation behaviour of the single-
walled carbon nanotube (SWCNT)-based drug carrier upon exposure to oxidative conditions 
mimicking oxidative burst of phagocytes, such as neutrophils (polymorphonuclear 
phagocytes) and monocytes/macrophages that are important components of white blood 
cells and different tissues. Here, we employ Doxorubicin (DOX) as a prototypical payload 
for a model drug delivery system (DOX-SWCNT), which constitutes an oxidized single-
walled nanotube (ox-SWCNT) and a branched phospholipid-polyethylene glycol (PL-PEG) 
that has demonstrated excellent in vivo clearance and circulation times.14–18 When drug 
nanocarriers are administered, the innate immune system recognizes them as a foreign 
substance and pathogens,19–21 which can elicit unwanted immune responses to the drug.22 
Thus, understanding the oxidative metabolism of DOX-SWCNT will provide insights into 
designing smart drug delivery systems that impart with maximum drug resistance towards 
the innate immune system prior to the timely degradation of nanocarriers. Our study aims at 
investigating the oxidation of DOX-SWCNT under the oxidative burst. For oxidative 
conditions, we chose (1) myeloperoxidase and hydrogen peroxide in the presence of chloride 
(MPO/H2O2/Cl−) and (2) peroxynitrite (ONOO−), which neutrophils and macrophages 
spontaneously release to intra- and extracellular domains during the host-immune response, 
particularly phagocytosis.23,24 The MPO highly expressed in neutrophils catalyses the 
oxidation of chloride (Cl−) with endogenous hydrogen peroxide (H2O2), which is further 
converted to hypochlorite/hypochlorous acid (−OCl/HOCl) at physiological conditions.25,26 
Macrophages produce peroxynitrite (ONOO−), which is formed in a reaction of nitric oxide 
(•NO) with superoxide (O2•−).24 The substances derived from the immune mechanism 
participate in antitumor as well as antimicrobial/anti-inflammatory activities.27,28 While 
large numbers of neutrophils and macrophages are localized in the tumor microenvironment, 
the therapeutic effects of drugs in the vicinity of these areas may be significantly reduced 
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due to increased oxidative activities by the strong oxidants.29–31 Our group and others 
demonstrated that these strong oxidants are responsible for degrading carbon 
nanotubes,5,6,32–34 and that oxidized carbon nanotubes were more susceptible to the 
biodegradation than pristine ones (non-functionalized nanotubes).35,36 In spite of the 
promising results, the structural change of drug carriers may cause the untimely clearance of 
drug molecules. Also, DOX bound to the nanotube carrier may simultaneously undergo 
degradation on its own under the same oxidative conditions, thereby dramatically altering 
their original pharmacokinetic properties.
Here, we have studied the degradation kinetics of DOX-SWCNT in comparison with that of 
free DOX, and have demonstrated that the degradation rates of the drug molecules differed. 
Upon exposure to either MPO/H2O2/Cl− or peroxynitrite (ONOO−), the drug molecules 
bound to the nanotube carrier exhibit slower oxidation rates than free DOX. On the other 
hand, non-oxidative conditions show pH- dependent degradation in which the degradation 
rates of DOX-SWCNT and free DOX are very similar.
DOX-SWCNT was synthesized following a published procedure.14,15 Pristine HiPco 
SWCNTs were oxidized using a mixture of concentrated H2SO4/HNO3 (3:1, v/v), yielding 
short oxidized nanotubes. PL-PEG (average MW ca. 7.4–8.2 KDa, Fig. S1) was synthesized 
by coupling a branched PEG with a phospholipid-tethered PEG (Fig. 1a). The ox-SWCNTs 
were non-covalently functionalized with PL-PEG prior to non- covalent conjugation with 
DOX. The degree of oxidation of pristine HiPco SWCNT was measured by Raman 
spectroscopy, Fourier transform infrared spectroscopy (FTIR), and X-ray photoelectron 
spectroscopy (XPS) (Fig. S2–S4). Fig. 1b–d show the transmission electron microscopy 
(TEM) images of each step of functionalization in the synthesis of DOX-SWCNT. Although 
most of the drug conjugate particles shown in Fig. 1d maintain high aspect ratios with an 
average length of 135 nm, agglomerates are relatively abundant.
UV-Vis-NIR absorption spectra confirm the presence of each component of the drug 
conjugate (Fig. 1e). The suppressed S11 optical transitions near 870–1100 nm are 
characteristic of oxidized HiPco SWCNTs,37 in which the broad absorption band constitutes 
the residual peaks of numerous chiral species (n,m).38 A slightly red-shifted DOX 
absorption maximum at 495 nm from the free DOX absorption (480 nm) is indicative of 
non-covalent adsorption of drug molecules on the surface of ox-SWCNT,39 which was 
further demonstrated by the quenched fluorescence emission of DOX via mainly π–π 
stacking40 at 555 and 595 nm (Fig. S5). The drug loading of DOX was measured by 
titrations using UV-Vis absorption spectroscopy (Fig. S6) and zeta potential analysis under 
pH 7.0 (Fig. S7). A binding ratio of DOX to the nanocarrier (weight of bound DOX/weight 
of ox-SWCNT/PL-PEG) was found to be approximately 1:1.
Next, we investigated the degradation profiles of the nanotube and DOX in phosphate buffer 
solution (0.1 M, pH 7.4) by monitoring spectral changes in UV-Vis-NIR absorption 
spectroscopy. Each sample contained NaCl (0.14 M) as a chloride source and 
diethylenetriamine pentaacetic acid (DTPA) as a chelating agent coordinating with residual 
transition metal catalyst ions present in the commercial HiPco nanotubes. The peroxidase-
catalysed oxidation cycle was initiated by addition of an aliquot of H2O2, which produced 
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hypochlorous acid/hypochlorite (HOCl/OCl−) equilibrating at pH 7.4 and reactive 
intermediate species (Fig. 2a).5,32 Hypochlorite (OCl−) can further induce oxidation, and 
MPO-I and MPO-II, each of which drives one-electron oxidation,41 promote the formation 
of reactive radical intermediates and electron transfer reactions.
The samples were incubated at 37 °C, and the resulting spectral changes were recorded 
periodically at room temperature. In the presence of MPO/H2O2/Cl−, Fig. 2b–c show 
decreases in absorbance of DOX at 495 nm and the S11 region (900–1100 nm) of ox-
SWCNT. The absorption profile of the residual peaks near 950 nm changed significantly. 
Likewise, the NIR absorbance of ox-SWCNT/PL-PEG (no drug) decreased, indicating that 
the nanotube surface coated with the PL-PEG had also undergone oxidative degradation, as 
demonstrated by TEM (Fig. S8). This result is in good agreement with previous degradation 
studies of PEG-SWCNTs that were non-covalently functionalized with PEGs of various 
molecular weights (ca. 600–10,000 Da).42,43
The dramatically different NIR absorption profiles over the course of degradation (Fig. 2c) 
suggest that the altered energy band gaps of the nanotubes possibly resulted from changes in 
the electronic structures and functional groups of the nanotube sidewall and ends. The 
oxidation of the drug carrier may disrupt the π-π stacking of DOX and initiate dissociations 
of the drug molecules from the nanotube surface. This observation further raises a concern 
that the drug molecules could be untimely released during circulation. However, the 
relatively small change in the DOX absorption at 495 nm (Fig. 2b) compared to free DOX 
(Fig. 2d) indicates that most drug molecules still remained intact during the oxidation 
process. In the presence of MPO/H2O2/Cl−, free DOX degraded about fourfold faster than 
DOX of the drug conjugate (Fig. 2e), which suggests that the nanotube carrier may serve as 
a scavenger for the strong oxidant (−OCl) and reactive intermediate species generated from 
the MPO cycle. Because phenolic derivatives are especially good reducing substrates for the 
conversion of MPO-I into MPO-II,44 ox-SWCNT carrier containing hydroxyl groups (Fig. 
S4b–c) can facilitate competing reactions with DOX. We propose the major chemical 
transformations of DOX in Scheme 1, where 1 is likely to undergo radical reactions due to 
the hydroquinone (B-ring) adjacent to the electrophilic quinone (C-ring) moieties. The one-
electron oxidation generates 2 (semiquinone (O•−) of Bring), and 3 can be formed through 
multiple steps by electron transfer and radical rearrangement on the carbons of A- and B-
ring in the presence of excess H2O or −OH.45 Further proposed degradation products and 
competing reactions are discussed in Supporting Information (Scheme S1).
Interestingly, except for the free DOX under the MPO-catalysed oxidation, the drug 
molecules in all other samples degraded relatively evenly, considering that the error bars 
slightly overlap with one another (Fig. 2e). These similar degradation patterns in the non-
enzymatic oxidative conditions for both free DOX and DOX-SWCNT samples indicate that 
DOX is somewhat unstable in the pH 7.4 buffer at 37 °C. We attributed this result to pH-
dependent degradation resulting from keto-enol tautomerization upon deprotonation at C14 
of 1, followed by deacetylation and deglycosylation.46 Our analyses with 1H NMR and 
LC/MS confirmed the formation of 4 (Fig. S9–S11).
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In the analysis of peroxynitrite-mediated oxidation, we utilized fluorescence emission 
spectroscopy to investigate the stability of DOX-SWCNT because the absorption band of 
the by-product overlapped with that of free DOX (Fig. S12). The drug conjugate was 
incubated in phosphate buffer (0.1 M, pH 7.4) at 37 °C. Peroxynitrite (ONOO−) was 
generated in situ by the reaction of superoxide radicals (O2•−) with nitric oxide (•NO) (Fig. 
3a), where xanthine oxidase (xo) catalyses the oxidation of xanthine and produces 
superoxide radicals; and N3-(2-hydroxy-2-nitroso-1-propylhydrazino)-1-propanamine 
(PAPA NONOate) serves as a nitric oxide donor.
As in the MPO-catalysed oxidation, the drug conjugate (DOX-SWCNT) shows a smaller 
change of DOX emission intensity than that of free DOX (Fig. 3b). It appears that the 
nanocarrier protects the drug molecules from the strong oxidant peroxynitrite (ONOO−). 
The NIR band profiles and the TEM images of degrading ox-SWCNT/PL-PEG listed in 
Supporting Information (Fig. S12 and S13) demonstrate that the nanocarrier was subject to 
structural transformation, where peroxynitrite (ONOO−) can promote (1) direct nucleophilic 
reactions and (2) one- or two-electron transfer oxidations.32
Peroxynitrite randomly diffuses through biological compartments and directly oxidizes 
SWCNTs. Similarly, HOCl produced during MPO catalytic cycle can permeate through the 
PEG-coated nanotubes, resulting in the stripping of PEG and biodegradation.43 However, 
MPO recognizes SWCNTs first, which is an electrostatically driven and selective process.5 
Once highly cationic MPO is placed in close proximity to ox-SWCNT (mostly present as 
SWCNT-COO− under pH 7.4), oxidation of the nanotubes occurs in the vicinity of the 
bound enzyme. However, as the surface charge of DOX-SWCNT is different from that of 
ox- SWCNT due to the functionalization with PL-PEG and DOX, we further implemented 
zeta potential analysis to characterize the surface charge of each functionalization and find 
the effective concentration range of MPO that can bind with the drug conjugate (Fig. 4).
PL-PEG and DOX reduced the negative charge effect of ox-SWCNT in the synthesis of 
DOX-SWCNT, as indicated in the zeta potential change from −48.3 mV to −14.2 mV (see 
Supporting Information, Table S1), which could further delay the MPO-catalysed oxidation. 
To analyse the threshold binding ratio of MPO to DOX-SWCNT, we performed zeta 
potential titration by gradually adding MPO to a DOX-SWCNT solution. It appears that the 
binding of MPO became saturated near 0.18 weight equiv. We chose 0.13 weight equiv 
(lower than the threshold value) for our degradation experiment, which probably resulted in 
the effective enzymatic oxidation with the drug conjugate. The fact that the addition of PL-
PEG did not completely prevent the binding with MPO is interesting although, according to 
the literature,47 some PEGs could reduce the non-specific interaction with MPO under 
certain circumstances.
To test whether cellular MPO- and peroxynitrite-dependent pathways may exhibit 
differential biodegradation activity towards free DOX and nanotube-bound DOX, we co-
cultured fluorescent dye labeled B16 melanoma cells with each of the DOX samples in the 
presence of bone marrow-derived tumor-activated myeloid-derived suppressor cell (MDSC) 
known to express high levels of MPO and iNOS.48 This implies that both MPO- and 
peroxynitrite-dependent oxidative biodegradation pathways are active in these cells. 
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Importantly, both MPO and iNOS expression are essential for the immune-suppressive 
function of MDSC during growth of the tumor in the host.49 Twenty-four hours later, DOX-
induced apoptosis was assessed in B16 melanoma cells by Annexin V binding (as described 
in Supporting Information). Fig. 5a demonstrates the results of a representative flow 
cytometry analysis, and Fig. 5b shows the summary results from the triplicated experiments. 
As expected, free DOX in moderate pharmacological dose of 5 μM increased the level of 
tumor cell death up to two-fold (p<0.01) whereas DOX-SWCNT was significantly more 
potent and caused an up to six-fold increase of apoptosis (p<0.01). The concentrations of 
DOX released from the nanotubes in the cell medium remained constant (about 1 μM) over 
24 h whereas free DOX concentrations were threefold higher than DOX-SWCNT initially 
and then dropped by about 50% after 24 h (Fig. S14). However, direct comparison of 
cytotoxic effect of free DOX or nanotube-bound DOX is not appropriate in cell cultures due 
to the differences in concentrations and dynamics of DOX degradation. Important is the fact 
that the addition of MDSC significantly abolished the cytotoxic effect of free DOX, but not 
nanotube-bound DOX, suggesting that the nanotube-bound cytotoxic drug exhibits a 
stronger antitumor potential in the in vitro model of the tumor microenvironment than the 
free chemotherapeutic agent. As shown in Fig. 5, the absence of the cytotoxic effects in all 
additional control groups (ox-SWCNT/PL-PEG, MDSC alone, and MDSC+ox-SWCNT/PL-
PEG) supports this conclusion.
The effects of free DOX and DOX-SWCNT on tumor cells in the presence of tumor-
activated MDSC was confirmed using another tumor cell line – 3LL Lewis lung carcinoma, 
where tumor cell proliferation was determined. As shown in Fig. S16, both free DOX and 
DOX-SWCNT decreased the number of 3LL cells in cultures up to two-fold (p<0.01). 
However, addition of MDSC abolished the cytostatic/cytotoxic effect of free DOX, but not 
DOX-SWCNT, suggesting that nanotube-bound DOX exhibits a significantly stronger 
antitumor potential than free DOX in the presence of tumor-activated MDSC expressing 
high levels of MPO and iNOS.
Conclusions
We have demonstrated a degradable carbon nanotube-drug conjugate (DOX-SWCNT) by 
MPO-catalysed and peroxynitrite-mediated oxidations. The degradation behaviour of free 
DOX was analysed in comparison to DOX-SWCNT under the same conditions, which 
allowed us to evaluate the effect of the nanotube carrier on the stability of DOX towards the 
oxidative reactions by enzymatic systems of innate immune cells—particularly neutrophils 
and macrophages. In both of the oxidative conditions, the drug molecules (DOX-SWCNT) 
degraded more slowly than free DOX. Our in vitro study also suggests that the 
chemotherapeutic agent delivered by the nanocarrier may be protected from the enzymatic 
inactivation associated with myeloid cells in the tumor microenvironment while exhibiting a 
constant DOX release rate. However, DOX demonstrated pH-dependent degradation in the 
non-oxidative conditions, and the nanotube carrier seems to be ineffective in slowing down 
this degradation process. Optimizing the balance between the degradation and resistance of 
the drug carrier and the payload towards the oxidants generated by inflammatory cells is 
critical to meet the needs for safety and prolonged circulation while orchestrating the 
stability and therapeutic effect of the drug. This strategy opens opportunities for exploring 
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new parameters in biodegradation and developing controllable degradation properties by 
chemical modification of the surface of nanotubes.
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(a) Chemical structures of the individual components, (b)–(d) TEM images of (b) oxidized 
HiPco (ox-SWCNT), (c) after functionalization with PL-PEG (ox-SWCNT/PL-PEG), and 
(d) loading with DOX/ox-SWCNT/PL-PEG (DOX-SWCNT). (e) UV-Vis-NIR absorption 
spectra for each functional nanomaterial. The spectra for SWCNT samples were normalized 
at 364 nm for comparison.
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MPO-catalysed oxidative degradation under pH 7.4 at 37 °C. (a) MPO catalytic cycle 
activated by H2O2 and production of HOCl. (b) Change in DOX absorbance (495 nm) and 
(c) S11 band (900–1100 nm) before and after 48 h. (d) Decreasing absorbance of free DOX 
over 20 h. (e) Degradation of DOX (free DOX vs. DOX-SWCNT) under four different 
conditions of (±) MPO/(±) H2O2. The error bars indicate the means ± SD of three replicate 
measurements.
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(a) Formation of peroxynitrite (b) Peroxynitrite-mediated degradation of free DOX vs. 
DOX-SWCNT in phosphate buffer (0.1 M, pH 7.4) at 37 °C. The error bars indicate the 
means ± SD of three replicate measurements.
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Zeta potential titration of the DOX-SWCNT with MPO at pH 7.4. Data are means ± SD of 
five replicate measurements.
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Fig. 5. Cytotoxic effects of free DOX vs. DOX-SWCNT in B16 melanoma cells and bone marrow-
derived, tumor-activated MDSC
DOX-SWCNT, but not free DOX, induces significant apoptosis of B16 melanoma cells 
even in the presence of MDSC. B16 melanoma cells and bone marrow-derived tumour-
activated MDSC were generated as described in Supporting Information and co-cultured in 
the presence of free DOX or DOX-SWCNT. ox-SWCNT/PL-PEG served as a control. The 
level of tumour cell apoptosis was determined 24 h later by Annexin V binding as described 
in Supporting Information. All cell cultures were set in triplicates, and results are shown as 
representative flow cytometry dot plots in (a) and the mean ± SEM (standard error of the 
mean) (N=3) in (b).*, p<0.01 versus control (medium) group (One way ANOVA).
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MPO-catalysed and pH-dependent degradation of DOX at pH 7.4.
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